Why human longevity drugs face an impossible patent catch-22
“I think, actually, the biggest issue is I think we have a little bit of a catch 22 with what kind of drug you develop for human longevity because, again, of this patent issue.”
And I think there's a lot of questions. Right? Like, do we explicitly look at mortality risk reduction? Right? So, like, your the risk of you dying in any one year and the ability of a drug to reduce that. Do we look at what we think are leading indicators of mortality risk reduction, but still more general than disease? Like, all of these things are gonna determine, so I can't really give you a a timeline for a human longevity trial right now. I think, actually, the biggest issue is I think we have a little bit of a catch 22 with what kind of drug you develop for human longevity because, again, of this patent issue. Right? You need and you need something
About this clip
Celine Halioua explains the complex regulatory and business challenges facing human longevity drug development. She discusses the difficulty of designing clinical trials when it's unclear whether to measure direct mortality reduction or leading indicators, and highlights how patent issues create a fundamental catch-22 for developing longevity treatments.
Why this clip
This clip reveals a fundamental structural problem in the longevity industry that most people don't realize exists.
More from this episode
From the blog
Want clips like this for your podcast?
We find your top 5-8 clips, write the hooks, and deliver ready-to-post content. First 2 episodes are free.
Get 2 Episodes Clipped Free